221 related articles for article (PubMed ID: 18349265)
21. Targeting prostate cancer bone metastases.
Logothetis C; Tu SM; Navone N
Cancer; 2003 Feb; 97(3 Suppl):785-8. PubMed ID: 12548576
[No Abstract] [Full Text] [Related]
22. Comments on plasma parathyroid hormone levels and their relationship to bone histopathology among patients undergoing dialysis.
Goodman WG
Semin Dial; 2007; 20(1):1-4. PubMed ID: 17244110
[TBL] [Abstract][Full Text] [Related]
23. Cancer and bone repair mechanism: clinical applications for hormone refractory prostate cancer.
Koutsilieris M; Mitsiades C; Lembessis P; Sourla A
J Musculoskelet Neuronal Interact; 2000 Sep; 1(1):15-7. PubMed ID: 15758519
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy.
Pinski J; Dorff TB
Eur J Cancer; 2005 Apr; 41(6):932-40. PubMed ID: 15808959
[TBL] [Abstract][Full Text] [Related]
25. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
Logothetis CJ; Navone NM; Lin SH
Clin Cancer Res; 2008 Mar; 14(6):1599-602. PubMed ID: 18347159
[TBL] [Abstract][Full Text] [Related]
26. Calcium malabsorption does not cause secondary hyperparathyroidism.
Nordin BE; Morris HA; Horowitz M; Coates PS; O'Loughlin PD; Need AG
Calcif Tissue Int; 2009 Jul; 85(1):31-6. PubMed ID: 19488668
[TBL] [Abstract][Full Text] [Related]
27. Bone directed therapies for prostate cancer.
Bradley DA; Hussain M; Dipaola RS; Kantoff P
J Urol; 2007 Sep; 178(3 Pt 2):S42-8. PubMed ID: 17644119
[TBL] [Abstract][Full Text] [Related]
28. [Mechanism and treatment of cancer metastasis to bone].
Yoneda T
Clin Calcium; 2005 Jul; 15(7):29-37. PubMed ID: 15995293
[TBL] [Abstract][Full Text] [Related]
29. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T
Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111
[TBL] [Abstract][Full Text] [Related]
30. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
31. Bone and prostate cancer cell interactions in metastatic prostate cancer.
Vela I; Gregory L; Gardiner EM; Clements JA; Nicol DL
BJU Int; 2007 Apr; 99(4):735-42. PubMed ID: 17166237
[TBL] [Abstract][Full Text] [Related]
32. Bone-directed treatments for prostate cancer.
Saad F
Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
[TBL] [Abstract][Full Text] [Related]
33. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
34. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
Darnel AD; Behmoaram E; Vollmer RT; Corcos J; Bijian K; Sircar K; Su J; Jiao J; Alaoui-Jamali MA; Bismar TA
Clin Cancer Res; 2009 Feb; 15(4):1376-83. PubMed ID: 19228738
[TBL] [Abstract][Full Text] [Related]
35. Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases.
Lindqvist O; Rasmussen BH; Widmark A
Eur J Oncol Nurs; 2008 Sep; 12(4):283-90. PubMed ID: 18440862
[TBL] [Abstract][Full Text] [Related]
36. Bone metastases in breast cancer, prostate cancer and myeloma.
Paterson AH
Bone; 1987; 8 Suppl 1():S17-22. PubMed ID: 3318889
[TBL] [Abstract][Full Text] [Related]
37. Bone turnover mediates preferential localization of prostate cancer in the skeleton.
Schneider A; Kalikin LM; Mattos AC; Keller ET; Allen MJ; Pienta KJ; McCauley LK
Endocrinology; 2005 Apr; 146(4):1727-36. PubMed ID: 15637291
[TBL] [Abstract][Full Text] [Related]
38. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.
Wakchoure S; Swain TM; Hentunen TA; Bauskin AR; Brown DA; Breit SN; Vuopala KS; Harris KW; Selander KS
Prostate; 2009 May; 69(6):652-61. PubMed ID: 19152406
[TBL] [Abstract][Full Text] [Related]
39. Bone imaging in prostate cancer.
Dotan ZA
Nat Clin Pract Urol; 2008 Aug; 5(8):434-44. PubMed ID: 18682719
[TBL] [Abstract][Full Text] [Related]
40. Hypocalcemia and parathyroid function in metastatic prostate cancer.
Tandon PK; Rizvi AA
Endocr Pract; 2005; 11(4):254-8. PubMed ID: 16006299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
